8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 21, 2008

Orchid Cellmark Inc.

(Exact name of the registrant as specified in its charter)

Delaware	000-30267	22-3392819
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4390 US Route One, Princeton, NJ 08540

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (609) 750-2200

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(a), (b), (d), (e) and (f): Not applicable.

(c) On May 27, 2008, Orchid Cellmark Inc. (the “Company”) announced the appointment of Jeffrey S. Boschwitz as Vice President of North America Marketing and Sales as of May 21, 2008.

Mr. Boschwitz, age 41, was most recently Director of Marketing, Planning, Analysis and Research, at Quest Diagnostics from 2005 to 2008. Prior to joining Quest Diagnostics, he was a Principal in Booz Allen Hamilton’s healthcare practice from 2000 to 2005. Mr. Boschwitz received a B.S. in Biology and a Ph.D. in Immunology from Cornell University.

There is no family relationship, arrangement or understanding between Mr. Boschwitz and any other person pursuant to which he was appointed as an executive officer of the Company.

Pursuant to the terms of an employment agreement between Mr. Boschwitz and the Company, Mr. Boschwitz will receive an annual salary of $230,000. Mr. Boschwitz also is eligible to receive an annual bonus of up to 25% of his annual base salary, pro rated for 2008. Under the agreement, Mr. Boschwitz has agreed to purchase $10,000 worth of the Company’s common stock on the open market within six months of his employment by the Company and the Company granted Mr. Boschwitz an option to purchase 50,000 shares of the Company’s common stock at an exercise price equal to the fair market value of the Company’s common stock as determined under the Company’s Amended and Restated 2005 Stock Plan, as amended. The option vests in 48 equal installments over four years and fully upon a change of control of the Company (as defined in the agreement). The agreement is for an initial term of three years and automatically extends for additional one-year periods unless the Company or Mr. Boschwitz provide notice to the other at least three months before the end of the current term that the agreement will not automatically extend beyond such current term. The Company may terminate the agreement upon notice to Mr. Boschwitz, and must provide Mr. Boschwitz six months of his base salary if it terminates Mr. Boschwitz without cause (as defined in the agreement). Mr. Boschwitz may terminate the agreement upon 30 days notice to the Company. In addition, in connection with the agreement, Mr. Boschwitz entered into an intellectual property, confidentiality, non-competition and non-solicitation agreement with the Company.

A copy of the press release announcing the appointment of Mr. Boschwitz is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release dated May 27, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Orchid Cellmark Inc.
Date: May 28, 2008	By:	/s/ William J. Thomas
	Name:	William J. Thomas
	Title:	Vice President and General Counsel

EXHIBIT INDEX

Exhibit No.	Exhibit
99.1	Press Release dated May 27, 2008.

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE

Orchid Cellmark, Inc.
(609) 750-2200
Investors:	Media:
Mary Bashore	Barbara Lindheim
(609) 750-2324	Gendel Lindheim BioCom Partners
	(212) 918-4650

ORCHID CELLMARK APPOINTS JEFFREY S. BOSCHWITZ AS VICE PRESIDENT, NORTH

AMERICA MARKETING & SALES

Princeton, NJ, May 27, 2008—Orchid Cellmark Inc. (Nasdaq:ORCH), a leading worldwide provider of identity DNA testing services, today announced a change in its sales and marketing organization.

Jeffrey S. Boschwitz, Ph.D. has been appointed Vice President of North America Marketing and Sales. Based in Orchid Cellmark’s corporate headquarters in Princeton New Jersey, Mr. Boschwitz will oversee sales and marketing for Orchid’s North America business.

Mr. Boschwitz brings extensive strategic marketing experience to Orchid Cellmark. Most recently, he served as Director of Marketing, Planning, Analysis and Research at Quest Diagnostics, for the company’s physician diagnostics business division. As part of that role, Mr. Boschwitz was responsible for development of the marketing plan and optimizing sales force effectiveness. Previously, Mr. Boschwitz was a Principal in Booz Allen Hamilton’s health care practice with a focus on the diagnostics and pharmaceutical industries. Earlier in his career, he was a Project Manager for Plan A Consulting, where he led projects to optimize the value of new product pipelines for both large and entrepreneurial life sciences companies. Mr. Boschwitz received a B.S. in biology and a Ph.D. in immunology from Cornell University and completed his postdoctoral work at Stanford University.

Thomas A. Bologna, Chief Executive Officer of Orchid Cellmark said, “We believe that Jeff’s combination of analytical skills and strategic insight will be of significant value in leading our North America marketing and sales activities. Jeff has achieved success across industries and sectors in developing and implementing a wide variety of innovative business solutions. We believe that his broad experience is consistent with the qualities that we are seeking for an individual to lead our North America marketing and sales efforts.”

About Orchid Cellmark

Orchid Cellmark is a leading provider of identity DNA testing services for the human identity and agriculture markets. In the human identity area, the company provides DNA testing services for forensic, family relationship and security applications. In the agriculture field, Orchid Cellmark provides DNA testing services for selective trait breeding. Orchid Cellmark’s strong market positions in these areas reflect the company’s accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise, and the world-renowned Cellmark brand that has been associated with exceptional quality, reliability and customer service for nearly two decades. More information on Orchid Cellmark can be found at www.orchid.com.

All statements in this press release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, risks and uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid Cellmark’s products and services, dependence on government funding and collaborations, regulatory approvals, competition, intellectual property of others, patent protection, litigation, the timing of release of federal funds, the timing and amount of contracts put up for bid, and Orchid Cellmark’s ability to successfully offer its services directly to U.K. police forces. These risks and other additional factors affecting these forward-looking statements and Orchid Cellmark’s business are discussed under the headings “Risks Related to Our Business” and “Risks Associated with Our Common Stock” in Orchid Cellmark’s Annual Report on Form 10-K for the year ended December 31, 2007, as filed with the Securities and Exchange Commission, and in other filings made by Orchid Cellmark with the Securities and Exchange Commission from time to time. Orchid Cellmark expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Orchid Cellmark’s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as may be required by law.

Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press release.